Technical Analysis for LGVN - Longeveron Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.62 | -5.82% | -0.10 |
Earnings due: May 10
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -5.82% | |
| NR7 | Range Contraction | -5.82% | |
| NR7-2 | Range Contraction | -5.82% | |
| Narrow Range Bar | Range Contraction | -5.82% | |
| Wide Bands | Range Expansion | -5.82% | |
| Down 3 Days in a Row | Weakness | -5.82% | |
| Down 4 Days in a Row | Weakness | -5.82% | |
| Down 5 Days in a Row | Weakness | -5.82% | |
| Oversold Stochastic | Weakness | -5.82% | |
| Calm After Storm | Range Contraction | -10.99% |
| Alert | Time |
|---|---|
| New 52 Week Low | about 3 hours ago |
| Down 5% | about 3 hours ago |
| Down 3% | about 3 hours ago |
| Fell Below Previous Day's Low | about 3 hours ago |
| Down 2 % | about 3 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/10/2024
Longeveron Inc. Description
Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Stem Cell Cell Therapy Cell Biology Acute Respiratory Distress Syndrome Mesenchymal Stem Cell Alzheimer’s Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 44.0 |
| 52 Week Low | 1.62 |
| Average Volume | 2,582,499 |
| 200-Day Moving Average | 16.48 |
| 50-Day Moving Average | 3.88 |
| 20-Day Moving Average | 2.34 |
| 10-Day Moving Average | 2.16 |
| Average True Range | 0.63 |
| RSI (14) | 37.50 |
| ADX | 46.68 |
| +DI | 36.28 |
| -DI | 20.99 |
| Chandelier Exit (Long, 3 ATRs) | 3.58 |
| Chandelier Exit (Short, 3 ATRs) | 3.51 |
| Upper Bollinger Bands | 3.40 |
| Lower Bollinger Band | 1.28 |
| Percent B (%b) | 0.21 |
| BandWidth | 90.29 |
| MACD Line | -0.62 |
| MACD Signal Line | -0.67 |
| MACD Histogram | 0.0503 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.95 | ||||
| Resistance 3 (R3) | 1.96 | 1.89 | 1.91 | ||
| Resistance 2 (R2) | 1.89 | 1.84 | 1.89 | 1.89 | |
| Resistance 1 (R1) | 1.81 | 1.80 | 1.78 | 1.80 | 1.88 |
| Pivot Point | 1.74 | 1.74 | 1.73 | 1.74 | 1.74 |
| Support 1 (S1) | 1.66 | 1.69 | 1.63 | 1.65 | 1.56 |
| Support 2 (S2) | 1.59 | 1.65 | 1.59 | 1.55 | |
| Support 3 (S3) | 1.51 | 1.59 | 1.53 | ||
| Support 4 (S4) | 1.50 |
